{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:39:13Z","timestamp":1778722753225,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"Summary<\/jats:title>Smouldering multiple myeloma (SMM<\/jats:styled-content>) is associated with increased risk of progression to multiple myeloma within 2\u00a0years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK<\/jats:styled-content>) cell stimulation and antibody\u2010dependent cellular cytotoxicity (ADCC<\/jats:styled-content>) in\u00a0vitro<\/jats:italic>. CD<\/jats:styled-content>56dim<\/jats:sup> (CD<\/jats:styled-content>56dim<\/jats:sup>\/CD<\/jats:styled-content>16+<\/jats:sup>\/CD<\/jats:styled-content>3\u2212<\/jats:sup>\/CD<\/jats:styled-content>45+<\/jats:sup>) NK<\/jats:styled-content> cells represent the primary subset responsible for elotuzumab\u2010induced ADCC<\/jats:styled-content>. In this phase II<\/jats:styled-content>, non\u2010randomized study (NCT<\/jats:styled-content>01441973), patients with SMM<\/jats:styled-content> received elotuzumab 20\u00a0mg\/kg intravenously (cycle 1: days 1, 8; monthly thereafter) or 10\u00a0mg\/kg (cycles 1, 2: weekly; every 2\u00a0weeks thereafter). The primary endpoint was the relationship between baseline proportion of bone marrow\u2010derived CD<\/jats:styled-content>56dim<\/jats:sup> NK<\/jats:styled-content> cells and maximal M protein reduction; secondary endpoints included overall response rate (ORR<\/jats:styled-content>) and progression\u2010free survival (PFS<\/jats:styled-content>). Fifteen patients received 20\u00a0mg\/kg and 16 received 10\u00a0mg\/kg; combined data arepresented. At database lock (DBL<\/jats:styled-content>, September 2014), no association was found between baseline CD<\/jats:styled-content>56dim<\/jats:sup> NK<\/jats:styled-content> cell proportion and maximal M protein reduction. With minimum 28\u00a0months' follow\u2010up (DBL<\/jats:styled-content>: January 2016), ORR<\/jats:styled-content> (90% CI<\/jats:styled-content>) was 10% (2\u00b77\u201323\u00b72) and 2\u2010year PFS<\/jats:styled-content> rate was 69% (52\u201381%). Upper respiratory tract infections occurred in 18\/31 (58%) patients. Four (13%) patients experienced infusion reactions, all grade 1\u20132. Elotuzumab plus lenalidomide\/dexamethasone is under investigation for SMM<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.15384","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T10:40:20Z","timestamp":1527590420000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study"],"prefix":"10.1111","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2934-6518","authenticated-orcid":false,"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[{"name":"The Tisch Cancer Institute, Mount Sinai Medical Center New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2052","authenticated-orcid":false,"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Harvard Medical School Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellice","family":"Wong","sequence":"additional","affiliation":[{"name":"Section\u00a0of Medical Oncology Department of Medicine Yale University New Haven CT USA"},{"name":"Department of Medicine VA Connecticut Healthcare System West Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Stockerl\u2010Goldstein","sequence":"additional","affiliation":[{"name":"Division of Oncology Washington University St Louis MO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Weill Cornell Medicine Cornell University New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Section\u00a0of Hematology Department of Medicine Yale University New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying\u2010Ming","family":"Jou","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers\u00a0Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Lynch","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers\u00a0Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Robbins","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers\u00a0Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Shelat","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers\u00a0Squibb Princeton NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Harvard Medical School Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Harvard Medical School Jerome Lipper Multiple Myeloma Center Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1182\/blood.V112.11.108.108","article-title":"Elotuzumab (HuLuc63) activates CD56dim natural killer cells and monocytes resulting in the release of IP\u201010 and MCP\u20101. (Abstract)","volume":"112","author":"Balasa B.","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1610-3"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164228"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.07.004"},{"key":"e_1_2_9_6_1","unstructured":"Bristol\u2010Myers Squibb. (2017).Empliciti\u2122 (elotuzumab) prescribing information. Available at:http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf(Accessed June 7 2017)."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.553000"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.49"},{"key":"e_1_2_9_10_1","unstructured":"European Medicines Agency. (2016).Elotuzumab: Summary of product characteristics. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf(Accessed May 26 2016)."},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.976.976"},{"key":"e_1_2_9_12_1","article-title":"Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high\u2010risk smoldering multiple myeloma [Oral 976]","author":"Ghobrial I.M.","year":"2016","journal-title":"58th Annual Meeting & Exposition of American Society of Hematology (ASH)"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.60"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70001-8"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03549.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0174-1"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30124-3"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3182-8"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1339853"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00197-0"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.236"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T18:32:38Z","timestamp":1694889158000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/bjh.15384"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15384","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"2017-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}